Posted: Aug 24, 2023
Screening for Lipid Disorders in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Janelle M Guirguis-Blake et al. JAMA 2023 7 (3) 261-274
Lipid screening in childhood and adolescence can lead to early dyslipidemia diagnosis. The long-term benefits of lipid screening and subsequent treatment in this population are uncertain. We reviewed benefits and harms of screening and treatment of pediatric dyslipidemia due to familial hypercholesterolemia (FH) and multifactorial dyslipidemia. We found no direct evidence on the benefits or harms of pediatric lipid screening was identified. While multifactorial dyslipidemia is common, no evidence was found that treatment is effective for this condition. In contrast, FH is relatively rare; evidence shows that statins reduce lipid levels in children with FH, and observational studies suggest that such treatment has long-term benefit for this condition.
Assessing statins use in a real-world primary care digital strategy: a cross-sectional analysis of a population-wide digital health approach
MJM Carrion et al, Lancet Regional Health, June 22, 2023
The digitization of the primary care system provides an opportunity to evaluate the current use of statins in secondary prevention populations (myocardial infarction or stroke). We conducted a cross-sectional study analysing anonymised data routinely collected by community health workers (CHW) between May 2016 and September 2021 to assess the proportion of self-reported statins use and associated factors. The analysis of a real-world database from a digitized primary care system, allowed us to identify a very low use of statins in secondary prevention patients, mostly influenced by socio-demographic factors and co-morbidities.
Cost-effectiveness and Return on Investment of a Nationwide Case-Finding Program for Familial Hypercholesterolemia in Children in the Netherlands.
Zanfina Ademi et al. JAMA Pediatr 2023 5
In this economic evaluation of a hypothetical population of 1000 FH children aged 10 years, nationwide case finding was associated with saved lives and improved quality of life over a lifetime. The incremental cost-effectiveness ratio for cascade screening and initiation of treatment with statins in children vs later detection and treatment was €9220 ($10?050) per quality-adjusted life-year gained, that from a health care perspective and a societal perspective was cost saving and the return on investment for the detection and treatment program for FH in children was €8.37 ($9.12).